الصفحة الرئيسية>>Signaling Pathways>> Others>>RO5256390

RO5256390

رقم الكتالوجGC37548

RO5256390 هو ناهض للمستقبلات النزرة المرتبطة بالأمين 1 (TAAR1) ، وهو مستقبل مقرون ببروتين G عالي المحافظة (GPCR) مرتبط بالأمينات النزرة الذاتية

Products are for research use only. Not for human use. We do not sell to patients.

RO5256390 التركيب الكيميائي

Cas No.: 1043495-96-0

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
119٫00
متوفر
5mg
108٫00
متوفر
10mg
173٫00
متوفر
25mg
342٫00
متوفر
100mg
693٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

RO5256390 is an agonist of trace amine-associated receptor 1 (TAAR1), a highly conserved G-protein-coupled receptor (GPCR) bound by endogenous trace amines.RO5256390 can be used to reduce multiple behavioral effects of drugs of abuse through their actions on the mesocorticolimbic system[1].RO5256390 is a modulator of monoaminergic neurotransmission, blocks psychostimulant-induced hyperactivity and produces a brain activation pattern reminiscent of the antipsychotic drug olanzapine, suggesting antipsychotic-like properties[2].

[1]. Ferragud A, et al. The Trace Amine-Associated Receptor 1 Agonist RO5256390 Blocks Compulsive, Binge-like Eating in Rats. Neuropsychopharmacology. 2017 Jun;42(7):1458-1470. [2]. Revel FG, et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry. 2013 May;18(5):543-56.

مراجعات

Review for RO5256390

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for RO5256390

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.